



HARMONIZED SYSTEM
COMMITTEE

-
31st Session
-

NC0670E1
(+ Annex)

O. Eng.

Brussels, 17 April 2003.

CLASSIFICATION OF NEW INN PRODUCTS (WHO LIST 87)

(Item V.3 on Agenda)

Reference document :

NS0080E2, Annex A/7 (SSC/18 – Report)

I. BACKGROUND

1. At the 18th Session of the Scientific Sub-Committee, the Sub-Committee was reminded that INN List 87 had been sent to administrations on 10 December 2002 and delegates had requested to submit comments by the end of February 2003 at the latest so that the Secretariat could prepare a working document for the Harmonized System Committee's 31st Session (see Annex A/7 to Doc. NS0080E2).
2. Since the next (19th) Session of the Scientific Sub-Committee will not be held before January 2004, it was the Secretariat's intention to submit the agreed classifications to the next (31st) Session of the Harmonized System Committee for decision, after obtaining the agreement of the Chairman of the Scientific Sub-Committee.

II. SECRETARIAT ACTION

3. As of mid-March 2003, the Secretariat had received comments from the **EC**, **Canada** and the **United States**. The Secretariat has reproduced the products listed in WHO List 87 in the Annex to this document and reflected the comments received from the above administrations therein. INNs on which there was consensus as to classification are indicated in **bold** type and identified as "Agreed classification" in the Remarks column. The Annex also incorporates the list of products for which there were doubts or different views on classification. The proposed classifications in these cases have been placed in square brackets.

Note : Shaded parts will be removed when documents are placed on the WCO documentation database available to the public.

File No. 2549

4. The proposed classifications, as set out in the Annex hereto, were forwarded to the Chairman of the Scientific Sub-Committee for agreement. They have also been sent to the delegates to the Scientific Sub-Committee with a view to having them convey their comments, if any, to the Harmonized System Committee.
5. On 31 March 2003, the Secretariat received a reply from the Chairman of the Scientific Sub-Committee, conveying his agreement to the “agreed classifications” indicated in **bold** type in the Annex. He also indicated that other products, where classifications were doubtful, should be discussed at the next Scientific Sub-Committee meeting in 2004.

III. SECRETARIAT COMMENTS

6. Since the Chairman of the Scientific Sub-Committee and 18 Contracting Parties (including the **15 Member states of the European Union**) have expressed their agreement with the “agreed classifications”, the Secretariat would invite the Committee to accept the proposed classifications for these **50 INN products** indicated in **bold** type in the Annex to this document.
7. The classification of the remaining 16 INN products (for which the proposed classifications have been placed in square brackets) will be submitted to the next (19th) Session of the Scientific Sub-Committee in January 2004.

IV. CONCLUSION

8. The Committee is invited to accept the classifications of 50 INN products as indicated in **bold** type in the Annex.

* * *

List of new INN products (WHO List 87)

INN	Proposed classification	Remarks
albaconazole	[2933.59] [2933.99] [2941.90]	
alvimopan	[2933.39] [2933.59]	
apaziquone	2933.99	Agreed classification
apolizumab	3002.10	Agreed classification
asenapine	2934.99	Agreed classification
axomadol	2922.50	Agreed classification
bifeprunox	2934.99	Agreed classification
canertinib	2934.99	Agreed classification
cefovecin	2941.90	Agreed classification
cethromycin	[2941.50] [2941.90]	
dabigatran etexilate	2933.39	Agreed classification
delucemine	2921.49	Agreed classification
ecromeximab	3002.10	Agreed classification
eculizumab	3002.10	Agreed classification
edotecarin	2934.99	Agreed classification
eglumegad	2922.49	Agreed classification
elzasonan	2934.99	Agreed classification
enecadin	2933.59	Agreed classification
ertiprotafib	2934.99	Agreed classification
eszopiclone	[2933.59] [2933.79]	
fandosentan	2934.99	Agreed classification
fontolizumab	3002.10	Agreed classification
garenoxacin	2933.49	Agreed classification
idusulfase	3507.90	Agreed classification
indiplon	2934.99	Agreed classification
inecalcitol	[2906.19] [2936.90]	
iroxanadine	2934.99	Agreed classification
lidorestat	2934.20	Agreed classification
liraglutide	[2924.29] [2933.29] [2937.50]	
lubazodone	2934.99	Agreed classification
lubiprostone	2937.50	Agreed classification
lumiracoxib	2922.49	Agreed classification
merimepodib	2934.99	Agreed classification
mozavaptan	[2937.19] [2933.99]	

INN	Proposed classification	Remarks
nalfurafine	[2934.99] [2939.19]	
naminidil	2926.90	Agreed classification
nemifitide	2933.99	Agreed classification
nortopixantrone	2933.99	Agreed classification
oblimersen	[2934.99] [3002.10]	
ortataxel	[2932.99] [2941.90]	
osemozotan	2932.99	Agreed classification
palindore	2934.99	Agreed classification
pascolizumab	3002.10	Agreed classification
pegaptanib	[2934.99] [3907.20]	
pegsunercept	[2934.99] [3002.10] [3907.20]	
perflubrodec	2903.47	Agreed classification
picoplatin	2843.90	Agreed classification
plevitrexed	[2933.59] [2933.99]	
pumosetrag	2934.99	Agreed classification
siplizumab	3002.10	Agreed classification
soraprazan	2933.99	Agreed classification
tacapenem	2941.90	Agreed classification
tapentadol	2922.29	Agreed classification
tecadenoson	2934.99	Agreed classification
tecalcet	2922.29	Agreed classification
teneliximab	3002.10	Agreed classification
topixantrone	2933.99	Agreed classification
toralizumab	3002.10	Agreed classification
torcetrapib	[2924.29] [2933.49]	
torcitabine	2934.99	Agreed classification
trabectedin	[2934.99] [2941.90]	
treprostinil	[2918.90] [2937.50]	
triplatin tetranitrate	2843.90	Agreed classification
tulathromycin	2941.90	Agreed classification
vapaliximab	3002.10	Agreed classification
vaespladib	2933.99	Agreed classification